Defence Therapeutics - President & CEO, Sébastien Plouffe
President & CEO, Sébastien Plouffe
Source: LinkedIn
Market Herald logo

Subscribe

Be the first with the news that moves the market
  • The US Patent and Trademark Office (USPTO) has issued a Notice of allowance for Defence Therapeutics’ (DTC) patent application
  • The patent application covers the use of Defence’s proprietary Accum technology to boost the effectiveness of cell or protein-based vaccine
  • The patent will allow Defence to expand the development of vaccines and therapies in the fields of cancer and infectious diseases
  • The global oncology market is expected to be worth around US$536.01 billion by 2029
  • Defence Therapeutics is a biotechnology company working on engineering next-generation vaccines and ADC products using its proprietary platform
  • Defence Therapeutics Inc. (DTC) opened trading at C$3.04

The U.S. Patent and Trademark Office (USPTO) has issued a Notice of allowance for Defence Therapeutics’ (DTC) patent application number 17/738,548.

The patent application covers the use of components of Defence’s proprietary Accum technology as a powerful “drop-in” enhancer ingredient to boost the immunogenicity and performance of virtually any cell-based or protein subunit vaccine, expanding on Defence’s vaccine platform technology.

The patent will allow Defence to expand the development of novel, safe, and effective vaccines and therapies in the fields of cancer and infectious diseases. In particular, the ability of Defence’s enhancer Accum technology to improve activation of antigen-specific CD4 and CD8 T cell responses. This creates opportunities for developing highly potent novel vaccines using Defence technologies.

Mr. Plouffe, CEO of Defence Therapeutics, remarked,

“The ability of Defence’s enhancer technology to greatly improve antigen loading on MHC molecules of antigen-presenting cells creates additional opportunities for improving upon existing vaccines, such as by reducing antigen dose, thereby lowering manufacturing costs and potentially diminishing patient adverse reactions. Defence’s innovation and contribution to scientific knowledge, as well as its expanding clinical and patent portfolio, are a testament to the company’s continual and rapid growth.”

The global oncology market is expected to be worth around US$536.01 billion by 2029, growing at a CAGR of 8.2 per cent from 2021 to 2030. Oncology is a branch of medicine that deals with the prevention, diagnosis, and treatment of cancer. 

Defence has initiated a project study outline with a world-renowned institution specializing in clinical cancer trial expertise, the study will lead to identifying the specific cancer target for the start of a clinical trial. 

Defence Therapeutics is a biotechnology company working on engineering next-generation vaccines and ADC products using its proprietary platform. The core of the Defence Therapeutics platform is the ACCUM technology, which enables precision delivery of vaccine antigens or ADCs in their intact form to target cells.

Defence Therapeutics Inc. (DTC) opened trading at C$3.04.


More From The Market Herald

" @ the Bell: Growth-sensitive stocks fluctuate on mega jobs report

Canada’s main stock index ended on the higher side of flat on Friday trading as strength in the energy and technology sectors was weighed against

" Aimia (TSX:AIM) sells $7.36M in shares to Mithaq Capital

Aimia (AIM) has sold approximately $7.36 million of its common shares to investor company Mithaq Capital SPC.

" Terra Firma Capital (TSXV:TII) appoints new board member

Terra Firma Capital (TII) appoints Mike Kirchmair as a member of the corporation’s board of directors.
Capital Power Corporation - The Whitla Wind Facility

" Capital Power (TSX:CPX) looks forward to protecting the environment

Capital Power Corporation (CPX) enters a 23-year clean electricity supply agreement with Public Services and Procurement Canada to protect the environment.